2022
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
Zeidan AM, Platzbecker U, Garcia-Manero G, Sekeres MA, Fenaux P, DeZern AE, Greenberg PL, Savona MR, Jurcic JG, Verma A, Mufti G, Buckstein R, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji RS. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood 2022, 140: 2170-2174. PMID: 35797468, PMCID: PMC10653038, DOI: 10.1182/blood.2022016171.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesLow-risk myelodysplasiaErythropoiesis-stimulating agentsEligible patientsTransfusion independenceMyelodysplastic syndromeLong-term benefitsLuspaterceptMedian durabilityRing sideroblastsPatientsIncremental benefitPlaceboSignificant minorityTherapyTransfusionMyelodysplasiaSideroblastsSyndromeTrialsWeeksMonths
2018
Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice
Shallis RM, Xu ML, Podoltsev NA, Curtis SA, Considine BT, Khanna SR, Siddon AJ, Zeidan AM. Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Annals Of Hematology 2018, 97: 2333-2343. PMID: 30109425, DOI: 10.1007/s00277-018-3474-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeSecondary myelodysplasiaSecondary causesAllogeneic hematopoietic cell transplantationDiagnosis of MDSRepresentative case seriesUnderlying myelodysplastic syndromeHematopoietic cell transplantationLack of efficacyHematologists/oncologistsMeticulous exclusionResultant cytopeniasIntensive chemotherapyCase seriesMorphologic reviewCell transplantationDiagnostic dilemmaSuch therapyMalignant processExpert hematopathologistsClinical practiceMyelodysplasiaCytogenetic abnormalitiesPatientsSpecialized physicians
1987
Histopathology of bone marrow in human immunodeficiency virus infXection
Delacrétaz F, Perey L, Schmidt P, Chave J, Costa J. Histopathology of bone marrow in human immunodeficiency virus infXection. Virchows Archiv A Pathological Anatomy And Histopathology 1987, 411: 543-551. PMID: 3118563, DOI: 10.1007/bf00713285.Peer-Reviewed Original ResearchConceptsHIV infectionMyelodysplastic featuresHistological featuresHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionBone marrow findingsBone marrow biopsyMarrow findingsMarrow biopsyHaematological abnormalitiesGelatinous transformationVirus infectionHaematological findingsPatientsBone marrowConspicuous findingInfectionCell linesFindingsCytopaeniaPlasmacytosisLymphocytosisBiopsyMyelodysplasiaHypercellularity
1981
Urinary undiversion in patients with myelodysplasia and neurogenic bladder dysfunction Report of a Workshop
Borden T, McGuire E, Woodside J, Allen T, Bauer S, Firlit C, Gonzales E, Kaplan W, King L, Klauber G, Perlmutter A, Thornbury J, Weiss R. Urinary undiversion in patients with myelodysplasia and neurogenic bladder dysfunction Report of a Workshop. Urology 1981, 18: 223-228. PMID: 7025417, DOI: 10.1016/0090-4295(81)90349-6.Peer-Reviewed Original ResearchConceptsUrinary undiversionReasonable surgical treatmentSuch reconstructive surgeryNeurogenic bladder dysfunctionBladder dysfunctionNeurogenic bladderAbsolute contraindicationSelect patientsMyelodysplastic patientsSurgical treatmentUrinary diversionReconstructive surgeryUndiversionPatientsRole of reconstructionContraindicationsBladderReportMyelodysplasiaSurgeryDysfunctionEvaluation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply